Skip to main content

Table 3 Comparison of changes from beginning to end of study in clinical outcomes between treatment and placebo groups

From: House dust mite barrier bedding for childhood asthma: randomised placebo controlled trial in primary care [ISRCTN63308372]

Medical outcome variable HDM Impermeable bedding, n = 23 Placebo bedding, n = 20 95% CI of difference Significance p
Mean change in 28-day PEF litres/min (sd) 16.38 (25.62) 13.68 (43.14) -25.15 to 19.75 0.81
Mean change in 28-day asthma symptom scores (sd) -3.40 (29.50) -18.10 (27.80) -33.16 to 3.86 0.12
Mean change in 28-day rhinitis symptom scores (sd) -31.14 (35.79) -22.67 (30.70) -13.15 to 30.09 0.43
Mean change in episodes of monthly night-time waking over 28-day period (sd) -0.64 (3.00) -0.94 (2.30) -2.05 to 1.93 0,43
Mean change in 28-day dose of inhaled steroids mcg (sd) -1815.91 (3861.45) -1039.00 (1881.15) -1128.58 to 2682.59 0.41
Median non-study GP consultations (range) 1 (0–5) 0 (0–5)   0.26
Total number of hospital admissions for asthma 0 0   1
Total number of courses of oral steroids for asthma 2 2   1